ARTICLE | Clinical News

AG-519: Additional Ph I data

December 9, 2016 8:26 PM UTC

Data from 40 healthy volunteers in the second part of a 3-part, double-blind, U.K. Phase I trial showed that twice-daily 10-375 mg doses of oral AG-519 for 14 days reduced mean blood 2,3-diphosphoglyc...

BCIQ Company Profiles

Agios Pharmaceuticals Inc.

BCIQ Target Profiles

Pyruvate kinase R